Last reviewed · How we verify
NCT06561763
TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma
Phase 3 trial testing Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine in High Risk Locally Advanced Nasopharyngeal Carcinoma in 416 participants. Not yet recruiting.
20 August 2028
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 416 |
| Start date | 20 August 2024 |
| Primary completion | 20 August 2028 |
| Estimated completion | 20 August 2031 |
Drugs / interventions tested
- Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine — full drug profile →
- Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine — full drug profile →
Conditions studied
- High Risk Locally Advanced Nasopharyngeal Carcinoma — all drugs for High Risk Locally Advanced Nasopharyngeal Carcinoma →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 65, any sex, with High Risk Locally Advanced Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
We expect to conduct a clinical trial in high-risk locally advanced nasopharyngeal carcinoma patients to explore the efficacy and safety of sequential radical radiotherapy treatment after induction chemotherapy (TPC vs. GP) with combination therapy of nivolumab and triprolizumab.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Novel Therapeutic Development for Nasopharyngeal Carcinoma.
Kim J, Lee Y, Kim S, Park JC. · · 2025 · PMID 41002550 · DOI 10.3390/curroncol32090479
Verify or expand the search:
- PubMed search for NCT06561763
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06561763 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 20 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06561763.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing